We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZTS:NYSEZoetis Inc. Analysis

Data as of 2026-08-30 - not real-time

$77.34

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Zoetis Inc. is priced at $77.34 and its moving averages line up in bearish order, the shorter trailing the longer. Over a rolling month the price has gained 1.0%. Momentum indicators put RSI at 53.3 (neutral) with MACD reading bullish. Price has been bracketed by support at $71.00 and resistance at $80.17.
Valuation screens as undervalued: a P/E of 12.6 sits below the sector average of 30.5. The average analyst target implies 24.1% above today's level. The 2.83% dividend yield looks covered by current payout levels.
The composite risk read is 6/10, putting it in elevated territory. With 30-day volatility of 37.8%, a beta of 0.58 and a maximum drawdown of 54.1%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.

Top Market Events

Animal health company Zoetis NYSE:ZTS fell short of the market’s revenue expectations in Q2 CY2026, with sales flat...The timing of Zoetis Inc.’s NYSE:ZTS latest regulatory win is particularly relevant for shareholders. Just one week...Despite a challenging US market and increased competition, Zoetis leverages its diversified portfolio and disciplined...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 104.14
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 12.6 versus sector average of 30.5
  • Trading below the 200-day average of 104.14

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 12.6 versus sector average of 30.5
  • Analyst targets imply +24.1% versus the current price
  • Profit margin of 27.7% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth-0.20%
Profit Margin27.68%
P/E Ratio12.6
ROE64.91%
ROA15.35%
Debt/Equity294.00
Op. Cash Flow$2.8B
Free Cash Flow$2.0B
Industry P/E30.5

Technical Analysis

TrendBearish
RSI53.3
Support$71.00
Resistance$80.17
MA 20$75.58
MA 50$75.67
MA 200$104.14
MACDBullish
VolumeDecreasing
Fear & Greed Index95.66

Valuation

Fair Value$44.30
Target Price$96.00
Upside/Downside24.13%
GradeUndervalued
TypeValue
Dividend Yield2.83%

Risk Assessment

Beta0.58
Volatility37.79%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.